We are live on ! Find out more
ATOS icon

Atossa Therapeutics

49 hedge funds and large institutions have $14.2M invested in Atossa Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,509% more call options, than puts

Call options by funds: $1.06M | Put options by funds: $66K

19% more capital invested

Capital invested by funds: $11.9M → $14.2M (+$2.29M)

0% less ownership

Funds ownership: 0.86%0.86% (-0%)

9% less funds holding

Funds holding: 5449 (-5)

56% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 18

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
49
Holders Change
-5
Holders Change %
-9.26%
% of All Funds
0.71%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
8
Reduced
18
Closed
8
Calls
$1.06M
Puts
$66K
Net Calls
+$996K
Net Calls Change
+$299K
Name Holding Trade Value Shares
Change
Change in
Stake
HighTower Advisors
51
HighTower Advisors
Illinois
-$15K -1,340 Closed
Jane Street
52
Jane Street
New York
-$12.7K -1,153 Closed
Victory Capital Management
53
Victory Capital Management
Texas
-$10.2K -922 Closed
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
-$76 -7 -54%

ATOS Hedge Fund Activity: Q4 2023 in Review

49 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2023, worth a combined $14.2M — up 19% from $11.9M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ATOS and 3 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 8 added.

The largest buyer was Bank of Montreal, opening a new position worth an estimated $254K. The largest seller was Millennium Management, cutting an estimated $138K.

  • 49 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2023, down from 54 in Q3 2023.
  • Funds reported $14.2M of Atossa Therapeutics stock for Q4 2023, up 19% quarter-over-quarter.
  • 3 funds opened new Atossa Therapeutics positions in Q4 2023 and 8 closed out, a net change of -5 holders.
  • The largest Atossa Therapeutics buyer in Q4 2023 was Bank of Montreal, an estimated $254K added.
  • The largest Atossa Therapeutics seller in Q4 2023 was Millennium Management, an estimated $138K sold.

Based on aggregated 13F filings for Q4 2023.